Rezolute, Inc.

52 articles about Rezolute, Inc.

• Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day

  11/17/2023

  Rezolute, Inc. today announced that the management team will participate in BTIG’s 3rd Annual Ophthalmology Day, taking place virtually on November 27th.

• Rezolute Reports First Quarter Fiscal 2024 Results

  11/13/2023

  Rezolute, Inc., a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, announced its financial results for the first quarter of fiscal 2024 ended September 30, 2023.

• Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism

  10/17/2023

  Rezolute, Inc. announced that the European Medicines Agency has granted Priority Medicines eligibility to RZ358 for the treatment of congenital hyperinsulinism.

• Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism

  10/11/2023

  Rezolute, Inc. announced results following administration of RZ358 to a patient with refractory hypoglycemia due to tumor-mediated hyperinsulinism on a compassionate-use basis, under its expanded access program.

• Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress Planning to initiate Phase 3 Study for RZ358 (“sunRIZE study”) in the fourth quarter of 2023

  9/14/2023

  Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt treatment paradigms for devastating metabolic diseases, today announced its financial results for the fourth quarter and full fiscal year ended June 30, 2023.

• Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism

  6/27/2023

  Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today provided an update on its clinical development plans for RZ358, the Company’s product candidate for congenital hyperinsulinism (congenital HI).

• Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress

  5/11/2023

  Rezolute, Inc. announced its financial results for the third quarter of fiscal 2023 ended March 31, 2023.

• Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema

  3/23/2023

  Rezolute, Inc. hosted a virtual key opinion leader event focused on the therapeutic landscape of Diabetic Macular Edema, scientific rationale for an oral plasma kallikrein inhibitor to target the disease, and the potential of RZ402, the company’s oral PKI, to change the standard of care as a safe, effective, and less invasive treatment option.

• Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert

  3/8/2023

  Rezolute, Inc. will host a virtual event to highlight the Company’s RZ402 Phase 2 clinical program and the rationale for an oral plasma kallikrein inhibitor (PKI) in diabetic macular edema (DME) on Wednesday, March 22, 2023, from 4:30 p.m.

• Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress

  2/10/2023

  Rezolute, Inc. announced its financial results for the second quarter of fiscal 2023 ended December 31, 2022.

• Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular EdemaRZ402 is an oral therapy being developed as a potential alternative to invasive and suboptimal injections into the eye

  12/15/2022

  Rezolute, Inc. today announced that the Company has initiated a Phase 2 proof-of-concept study for RZ402, a plasma kallikrein inhibitor (PKI) being developed as an oral therapy for the treatment of Diabetic Macular Edema (DME).

• Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress

  11/9/2022

  Rezolute, Inc.  (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, today announced its financial results for the first quarter of fiscal 2023 ended September 30, 2022.

• Rezolute to Present at the Jefferies 2022 London Healthcare Conference

  11/1/2022

  Rezolute, Inc. announced that Nevan Charles Elam, Chief Executive Officer and Founder, will participate in a fireside chat at the Jefferies London Healthcare Conference on Thursday, November 17, 2022, at 11:25 a.m. EST/4:25 p.m. GMT.

• Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting

  10/20/2022

  Rezolute, Inc. today announced it will present clinical data from its Phase 1b multiple-ascending dose (MAD) study of RZ402 in Diabetic Macular Edema (DME) in a podium presentation at The Retina Society 55th Annual Scientific Meeting.

• Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress

  9/15/2022

  Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, today announced its financial results for the fourth quarter and full fiscal year ended June 30, 2022.

• Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer

  6/1/2022

  Rezolute, Inc., a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, announced that Brian Roberts, M.D., previously Senior Vice President and Head of Clinical Development, has been promoted to Chief Medical Officer.

• Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress

  5/12/2022

  Rezolute, Inc. announced its financial results for the third quarter of fiscal 2022 ended March 31, 2022.

• Rezolute, Inc. Announces Closing of Registered Direct Offering - May 04, 2022

  5/4/2022

  Rezolute, Inc. announced the closing of its previously announced underwritten registered direct offering of an aggregate of 18,026,315 shares of its common stock at an offering price of $3.80 per share.

• Rezolute to Host Corporate Update Call on May 4, 2022Company to Host Analyst and Investor Conference Call on Wednesday, May 4 at 4:30 p.m. ET

  5/4/2022

  Rezolute, Inc. announced that management will be hosting a corporate update call.

• Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism

  5/1/2022

  Rezolute, Inc. announced positive results from its Phase 2b RIZE study of RZ358 in patients with congenital hyperinsulinism, which were unveiled today in a late-breaking oral presentation at the Pediatric Endocrine Society 2022 Annual Meeting.